Cerenovus
Johnson & Johnson (NYSE:JNJ) announced in July 2017 that it’s medical device division is rolling the Pulsar Vascular and Neuravi acquisitions, as well as its existing Codman Neuro neurological portfolio, into a new neurovascular business dubbed Cerenovus.
The name Cerenovus, is derived from the Latin words for ‘new’ and ‘brain’ and will focus on hemorrhagic and ischemic stroke.
The business is being renamed in part to coincide with the company’s $1 billion divestiture of its Codman neurosurgery business to Integra Lifesciences.